Skip to content

Study · Non-randomized trial · n = 11 · 2016

8 results

Mitigating Meal-Related Glycemic Excursions in an Insulin-Sparing Manner During Closed-Loop Insulin Delivery: The Beneficial Effects of Adjunctive Pramlintide and Liraglutide.

Sherr JL, Patel NS, Michaud CI, Palau-Collazo MM, Van Name MA, Tamborlane WV, Cengiz E, Carria LR, Tichy EM, Weinzimer SA

Diabetes care5 May 2016Cited by 72 (Europe PMC)

PMID27208332 (opens in a new tab)PMCIDPMC4915555 (opens in a new tab)DOI10.2337/dc16-0089 (opens in a new tab)PepBankPUB-27208332
Source linkPubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In young adults with type 1 diabetes on closed-loop insulin delivery, adding liraglutide reduced meal-related plasma glucose excursions.

    In plain wordsIn young people with type 1 diabetes using closed-loop insulin, adding liraglutide reduced glucose rises after meals.

    Peptide
    Liraglutide
    Outcome
    DecreasePlasma glucose excursions during closed-loop
    Study

    n = 11

    Comparator
    Closed loop alone before liraglutide
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.8 mg · 3-4 weeks of dose escalationAs given in this study (human).

    Source sentences

    Summary
    CL + L also led to reductions in PG excursions (P = 0.05) and incremental PG AUC (P = 0.004), with a 28% reduction in prandial insulin delivery.
    1 context sentence
    Summary · context
    Eleven subjects (age 18-27 years; A1C 7.5 ± 0.9% [58 ± 9.8 mmol/mol]) were studied before and after treatment with 1.8 mg liraglutide (CL + L) after a similar 3-4-week dose escalation period.
  2. 02HumanNon-randomized trialEfficacy outcome

    In young adults with type 1 diabetes on closed-loop insulin delivery, adding liraglutide reduced the incremental plasma glucose AUC.

    In plain wordsIn young people with type 1 diabetes using closed-loop insulin, adding liraglutide reduced the total glucose rise after meals.

    Peptide
    Liraglutide
    Outcome
    DecreaseIncremental plasma glucose AUC
    Study

    n = 11

    Comparator
    Closed loop alone before liraglutide
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.8 mg · 3-4 weeks of dose escalationAs given in this study (human).

    Source sentences

    Summary
    CL + L also led to reductions in PG excursions (P = 0.05) and incremental PG AUC (P = 0.004), with a 28% reduction in prandial insulin delivery.
    1 context sentence
    Summary · context
    Eleven subjects (age 18-27 years; A1C 7.5 ± 0.9% [58 ± 9.8 mmol/mol]) were studied before and after treatment with 1.8 mg liraglutide (CL + L) after a similar 3-4-week dose escalation period.
  3. 03HumanNon-randomized trialEfficacy outcome

    In young adults with type 1 diabetes on closed-loop insulin delivery, adding liraglutide reduced prandial insulin delivery.

    In plain wordsIn young people with type 1 diabetes using closed-loop insulin, adding liraglutide reduced the mealtime insulin needed.

    Peptide
    Liraglutide
    Outcome
    DecreasePrandial insulin delivery
    Study

    n = 11

    Comparator
    Closed loop alone before liraglutide
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.8 mg · 3-4 weeks of dose escalationAs given in this study (human).

    Measurements

    Reduction in prandial insulin delivery
    28%
    CL + L

    Source sentences

    Summary
    CL + L also led to reductions in PG excursions (P = 0.05) and incremental PG AUC (P = 0.004), with a 28% reduction in prandial insulin delivery.
    1 context sentence
    Summary · context
    Eleven subjects (age 18-27 years; A1C 7.5 ± 0.9% [58 ± 9.8 mmol/mol]) were studied before and after treatment with 1.8 mg liraglutide (CL + L) after a similar 3-4-week dose escalation period.
  4. 04HumanNon-randomized trialEfficacy outcome

    In young adults with type 1 diabetes, outpatient liraglutide therapy led to weight loss.

    In plain wordsIn young people with type 1 diabetes, liraglutide treatment led to weight loss.

    Peptide
    Liraglutide
    Outcome
    DecreaseWeight change with outpatient liraglutide
    Study

    n = 11

    Comparator
    Closed loop alone before liraglutide
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    1.8 mg · 3-4 weeks of dose escalationAs given in this study (human).

    Measurements

    Weight loss
    3.2 kg
    outpatient liraglutide

    Source sentences

    Summary
    Outpatient liraglutide therapy led to a weight loss of 3.2 ± 1.8 kg, with a 26% reduction in total daily insulin dose.
    1 context sentence
    Summary · context
    Eleven subjects (age 18-27 years; A1C 7.5 ± 0.9% [58 ± 9.8 mmol/mol]) were studied before and after treatment with 1.8 mg liraglutide (CL + L) after a similar 3-4-week dose escalation period.
  5. 05HumanNon-randomized trialEfficacy outcome

    In young adults with type 1 diabetes, outpatient liraglutide therapy led to a lower total daily insulin dose.

    In plain wordsIn young people with type 1 diabetes, liraglutide treatment reduced the total insulin needed each day.

    Peptide
    Liraglutide
    Outcome
    DecreaseTotal daily insulin dose
    Study

    n = 11

    Comparator
    Closed loop alone before liraglutide
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.8 mg · 3-4 weeks of dose escalationAs given in this study (human).

    Measurements

    Reduction in total daily insulin dose
    26%
    outpatient liraglutide

    Source sentences

    Summary
    Outpatient liraglutide therapy led to a weight loss of 3.2 ± 1.8 kg, with a 26% reduction in total daily insulin dose.
    1 context sentence
    Summary · context
    Eleven subjects (age 18-27 years; A1C 7.5 ± 0.9% [58 ± 9.8 mmol/mol]) were studied before and after treatment with 1.8 mg liraglutide (CL + L) after a similar 3-4-week dose escalation period.
  6. 06HumanNon-randomized trialEfficacy outcome

    In subjects during closed-loop insulin delivery, adjunctive pramlintide delayed peak plasma glucose excursion compared with insulin delivery alone.

    In plain wordsIn subjects using closed-loop insulin, pramlintide delayed the blood sugar peak compared with insulin alone.

    Peptide
    Pramlintide (Symlin)
    Outcome
    IncreaseTime to peak plasma glucose excursion
    Study

    n = 10

    Comparator
    Closed-loop insulin delivery alone
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    60 μg · 3-4-week outpatient dose escalation before a 24-h closed-loop sessionAs given in this study (human).

    Measurements

    Time to peak glucose excursion
    1.6 h
    closed-loop insulin alone
    Time to peak glucose excursion
    2.6 h
    closed-loop insulin plus pramlintide
    P value
    < 0.001
    between sessions

    Source sentences

    Summary
    Pramlintide delayed the time to peak plasma glucose (PG) excursion (CL 1.6 ± 0.5 h vs. CL + P 2.6 ± 0.9 h, P < 0.001)
    1 context sentence
    Summary · context
    Ten subjects (age 16-23 years; A1C 7.2 ± 0.6% [55 ± 6.6 mmol/mol]) completed two 24-h sessions: one on CL alone and one on CL plus 60-μg pramlintide (CL + P), after a 3-4-week outpatient dose escalation.
  7. 07HumanNon-randomized trialEfficacy outcome

    In subjects during closed-loop insulin delivery, adjunctive pramlintide reduced peak postprandial glucose increments compared with insulin delivery alone.

    In plain wordsIn subjects using closed-loop insulin, pramlintide reduced peak blood sugar rises after meals compared with insulin alone.

    Peptide
    Pramlintide (Symlin)
    Outcome
    DecreasePeak postprandial plasma glucose increment
    Study

    n = 10

    Comparator
    Closed-loop insulin delivery alone
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    60 μg · 3-4-week outpatient dose escalation before a 24-h closed-loop sessionAs given in this study (human).

    Measurements

    P value
    < 0.0001
    peak postprandial glucose increment

    Source sentences

    Summary
    with concomitant blunting of peak postprandial increments in PG (P < 0.0001)
    1 context sentence
    Summary · context
    Ten subjects (age 16-23 years; A1C 7.2 ± 0.6% [55 ± 6.6 mmol/mol]) completed two 24-h sessions: one on CL alone and one on CL plus 60-μg pramlintide (CL + P), after a 3-4-week outpatient dose escalation.
  8. 08HumanNon-randomized trialEfficacy outcome

    In subjects during closed-loop insulin delivery, adjunctive pramlintide reduced postmeal incremental glucose area under the curve compared with insulin delivery alone.

    In plain wordsIn subjects using closed-loop insulin, pramlintide reduced the overall blood sugar rise after meals compared with insulin alone.

    Peptide
    Pramlintide (Symlin)
    Outcome
    DecreasePostmeal incremental plasma glucose AUC
    Study

    n = 10

    Comparator
    Closed-loop insulin delivery alone
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    60 μg · 3-4-week outpatient dose escalation before a 24-h closed-loop sessionAs given in this study (human).

    Measurements

    P value
    0.0002
    postmeal incremental glucose AUC

    Source sentences

    Summary
    and reductions in postmeal incremental PG area under the curve (AUC) (P = 0.0002).
    1 context sentence
    Summary · context
    Ten subjects (age 16-23 years; A1C 7.2 ± 0.6% [55 ± 6.6 mmol/mol]) completed two 24-h sessions: one on CL alone and one on CL plus 60-μg pramlintide (CL + P), after a 3-4-week outpatient dose escalation.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Versions 4 to 8Current

    28 Oct 2026, 02:03 UTC

    The same notice was added 5 times, first on 22 Oct 2026, 02:26 UTC. The status did not change between them.

    Study results updated

  2. Version 3

    21 Oct 2026, 18:59 UTC

    Study data updated · source update from Europe PMC

  3. Version 2

    12 Oct 2026, 12:10 UTC

    Study results updated

  4. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.